INSULINAS ANÁLOGAS DE AÇÃO RÁPIDA PARA O MANEJO DE PACIENTES COM HIPERGLICEMIA HOSPITALAR

Abstract

NATS-Humap/UFMS recommends the temporary use of rapid-acting insulin analogs in situations of regular human insulin shortages, considering similar efficacy and safety. Prioritize the safest product among those already incorporated, especially for pregnant women (insulin aspart) and children, with attention to the budgetary impact, given that there is no provision for specific reimbursement by the SUS. The recommendation, aligned with Conitec's deliberation, aims to ensure continuity of care, patient safety, and hospital planning in emergency scenarios, highlighting the importance of clinical and pharmacoeconomic monitoring to ensure rational and sustainable use in the hospital setting.